New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 23, 2014
10:02 EDTGT, ENDP, CBI, ARCP, VRX, PRGO, MW, HST, ESS, DRH, BR, ACT, TEVA, PKY, MNK, HSP, EQR, CTB, BDN, VTR, SLXP, MYL, JECOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Actavis (ACT) initiated with a Buy at Deutsche Bank... American Realty (ARCP) initiated with a Perform at Oppenheimer... Brandywine Realty (BDN) initiated with a Neutral at Mizuho... Broadridge (BR) initiated with an Outperform at Raymond James... Chicago Bridge & Iron (CBI) initiated with a Market Perform at Wells Fargo... Cooper Tire (CTB) initiated with a Neutral at JPMorgan... DiamondRock (DRH) initiated with a Neutral at ISI Group... Endo (ENDP) initiated with a Buy at Deutsche Bank... Equity Residential (EQR) initiated with a Neutral at Mizuho... Essex Property Trust (ESS) initiated with a Buy at Mizuho... Fluor (FLR) initiated with an Outperform at Wells Fargo... Goodyear Tire (GT) initiated with an Overweight at JPMorgan... Hospira (HSP) initiated with a Hold at Deutsche Bank... Host Hotels (HST) initiated with a Neutral at ISI Group... Jacobs Engineering (JEC) initiated with an Outperform at Wells Fargo... Jazz Pharmaceutical initiated with a Buy at Buckingham... Mallinckrodt (MNK) initiated with a Buy at Deutsche Bank... Men's Wearhouse (MW) reinstated with a Buy at Goldman... Mylan (MYL) initiated with a Buy at Deutsche Bank... Parkway Properties (PKY) initiated with a Neutral at Mizuho... Perrigo (PRGO) initiated with a Buy at Deutsche Bank... Salix (SLXP) initiated with a Hold at Deutsche Bank... Teva (TEVA) initiated with a Buy at Deutsche Bank... Valeant (VRX) initiated with a Hold at Deutsche Bank... Ventas (VTR) initiated with a Buy at Mizuho.
News For ACT;ARCP;BDN;BR;CBI;CTB;DRH;ENDP;EQR;ESS;GT;HSP;HST;JEC;MNK;MW;MYL;PKY;PRGO;SLXP;TEVA;VRX;VTR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
December 9, 2014
07:08 EDTENDPEndo completes acquisition of rights to Natesto from Trimel BioPharma
Endo International announced the completion of the acquisition of rights to Natesto, a testosterone nasal gel, the first and only testosterone nasal gel for replacement therapy in adult males diagnosed with hypogonadism, from Trimel BioPharma, a wholly-owned subsidiary of Trimel Pharmaceuticals for $25M including additional payments upon the achievement of certain regulatory and sales milestones. Endo will collaborate with Trimel on all regulatory and clinical development activities regarding Natesto. Endo intends to launch the product, through its Endo Pharmaceuticals subsidiary, in the Q1 of 2015.
06:39 EDTVRXValeant to abandon growth by acquisitions strategy, Reuters says
Subscribe for More Information
06:14 EDTACTAllergan price target raised to $245 from $210 at Citigroup
Subscribe for More Information
December 8, 2014
19:00 EDTHSPCubist CEO says Cubicin patent ruling will not affect Merck transaction
Subscribe for More Information
18:24 EDTHSPOn The Fly: After Hours Movers
Subscribe for More Information
18:00 EDTHSPCubist loses bid to stop Hospira's generic Cubicin after 2016, Bloomberg says
Cubist's (CBST) patent for Cubicin that expires in June 2016 upheld by judge, Bloomberg added. Note that this morning Merck (MRK) and Cubist Pharmaceuticals announced that the companies have entered into a definitive agreement under which Merck will acquire Cubist for $102 per share in cash.
17:54 EDTHSPFour Cubist Cubicin patents invalidated as Hospira wins ruling, Bloomberg says
Subscribe for More Information
17:30 EDTHSPMerck shares lower after reports of judge decision in Cubist/Hospira case
Subscribe for More Information
17:03 EDTHSPJudge may have found in favor of Hospira in Cubist case,CNBC's Meg Tirrell says
CNBC's Meg Tirrell said in a tweet: "Whoa. $CBST Hospira decision out -- "appears judge may have found in favor of Hospira on several points," ISI's @MarkSchoenebaum says." Reference Link
12:25 EDTACTAntibiotic makers rise after Merck agrees to buy Cubist
Subscribe for More Information
11:30 EDTMYL, ACT, TEVALeerink generics pharmaceutical analyst holds analyst/industry conference call
Subscribe for More Information
09:32 EDTENDPSyneron Medical signs agreement with AMS to supply holmium laser for urology
Subscribe for More Information
08:21 EDTTEVA, HSPMerck says looked at all risks, including patent litgation, before Cubist deal
Subscribe for More Information
07:19 EDTBRBroadridge to host investor meeting
Subscribe for More Information
06:47 EDTTEVAArena says Teva files marketing authorization of Belviq in Israel
Arena Pharmaceuticals (ARNA) disclosed late Friday that Teva Pharmaceutical's (TEVA) local Israeli subsidiary, Abic Marketing Limited, has filed for marketing authorization of Belviq in Israel. In connection with the filing, Arena will receive a milestone payment of $250K.
December 5, 2014
17:04 EDTVTRVentas files to sell 148,241 shares of common stock for holders
Subscribe for More Information
16:49 EDTACTAdvisory Committee recommends approval Of Actavis' ceftazidime-avibactam
Actavis announced that the Anti-Infective Drugs Advisory Committee convened by the U.S. Food and Drug Administration has voted to recommend approval of Actavis' New Drug Application for ceftazidime-avibactam, an investigational antibiotic being developed to treat hospitalized patients when limited or no treatment options are available for complicated intra-abdominal infections and complicated urinary tract infections caused by Gram-negative pathogens. The committee found the scientific and clinical evidence submitted by Cerexa, a wholly owned subsidiary of Actavis, adequately demonstrated the safety and efficacy of ceftazidime-avibactam in the treatment of the proposed cIAI and cUTI indications. The committee voted not to recommend approval of the combination for hospital-acquired bacterial pneumonia /ventilator-associated bacterial pneumonia and bacteremia.The Advisory Committee recommendation is not binding on the FDA, which makes the final decision regarding approval. Actavis expects FDA action on its NDA for ceftazidime-avibactam during the first quarter of 2015.
10:05 EDTMYLBristol-Myers jumps 2% amid talk of potential Pfizer bid
Shares of Bristol-Myers (BMY) are up in early trading amid chatter of a potential takeover bid from Pfizer (PFE). The stock is up $1.26 to $60.15. Bristol's market capitalization stands around $99B, less than twice that of Pfizer's $200B. A Jefferies analyst last week called Mylan (MYL) the most likely takeover target for Pfizer. Pfizer is "highly motivated" to buy a foreign company using its overseas cash and Mylan looks like the most likely target, Jefferies analyst Jeffrey Holford wrote.
08:23 EDTCTBCooper Tire examining changes to China production strategy, FT reports
Subscribe for More Information
07:54 EDTTEVALannett names Michael Bogda as president, effective December 1
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use